Lupus Cutaneous Erythematosus

Lupus Cutaneous Erythematosus Study
Focuses on individuals with skin manifestations of lupus, aiming to test innovative treatments, monitor skin health, and improve patient comfort and quality of life.

1. Skin Evaluation and Imaging

• Uses thorough skin exams and imaging to document rashes, lesions, and affected areas.

• Tracks changes and healing progress during treatment.
  
  

2. Symptom and Impact Monitoring

• Evaluates pain, itching, lesion severity, and the impact on daily activities.

• Provides regular assessments to measure both physical and emotional wellbeing.
  
  

3. Immune Marker & Inflammation Testing

• Monitors blood biomarkers for autoimmune activity and inflammation.

• Assesses patient response before, during, and after therapeutic interventions.
  
  

4. Clinical Therapy and Topical Trials

• Offers new pharmaceutical and topical treatments designed to control symptoms and prevent flare-ups.

• Ensures continuous supervision from medical specialists for therapy safety and effectiveness.
  
  

Eligible Participants Are

• 18 to 75 years of age

• Diagnosed with cutaneous lupus erythematosus (CLE) or systemic lupus with skin involvement

• Currently experiencing active skin rashes or lesions

• Not currently using certain immunosuppressive medications (restrictions may apply)

• Willing to undergo skin biopsies and regular blood tests

• Additional criteria apply
  
  

Eligible Participants May

• Receive study-related medical care and treatment at no cost

• Receive compensation for study-related time and travel

• Gain access to investigational treatments not yet available to the public

• Contribute to advancing medical research for lupus skin disease
  
  

The Lupus Cutaneous Erythematosus Clinical Trial advances medical understanding and treatment for lupus-related skin disease. Participation aids in developing targeted therapies that relieve symptoms, prevent complications, and support improved long-term skin health.